Related Experiment Video

Updated: Dec 16, 2025

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia
08:05

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia

Published on: December 19, 2020

14.6K

Massive Pulmonary Thromboembolism in Patients with COVID-19; Report of Three Cases

Mehdi Pishgahi1, Zahra Ansari Aval2, Behzad Hajimoradi3

  • 1Cardiology Department, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Archives of Academic Emergency Medicine
|July 3, 2020
PubMed

Insights

Severe COVID-19 cases can lead to pulmonary thromboembolism (PTE). Early anticoagulant prophylaxis with low-molecular-weight heparin (LMWH) is recommended for intensive care unit (ICU) patients to improve outcomes.

Area of Science:

  • Critical Care Medicine
  • Infectious Diseases
  • Cardiology

Background:

  • COVID-19 presents diverse clinical manifestations, with coagulopathies and thromboembolic events increasingly recognized as critical factors.
  • Understanding the link between severe COVID-19 and thrombotic complications is crucial for patient management.

Observation:

  • Three intensive care unit (ICU) patients with severe COVID-19 developed massive pulmonary thromboembolism (PTE) shortly after disease onset.
  • One patient experienced a fatal outcome, while two were successfully treated with thrombectomy and antithrombotic agents, respectively.

Findings:

  • Severe COVID-19 is associated with a significant risk of developing massive pulmonary thromboembolism (PTE).
  • Prompt medical intervention, including thrombectomy and antithrombotic therapy, can be effective in managing PTE in COVID-19 patients.

Implications:

  • Physicians should proactively consider and plan for anticoagulant prophylaxis, particularly using low-molecular-weight heparin (LMWH), in severe COVID-19 cases.
  • Early recognition and management of PTE are essential for improving prognosis in critically ill COVID-19 patients.

Keywords:
COVID-19Pulmonary embolismclinical deteriorationsevere acute respiratory syndrome coronavirus 2thrombolytic therapyvenous thromboembolism

More Related Videos

A Porcine Model of Acute Autologous Pulmonary Embolism07:44

A Porcine Model of Acute Autologous Pulmonary Embolism

Published on: September 6, 2024

704
Establishment of a Minimally Invasive Rat Model of Pulmonary Embolism Using Autologous Blood Clots08:02

Establishment of a Minimally Invasive Rat Model of Pulmonary Embolism Using Autologous Blood Clots

Published on: October 25, 2024

661

Related Concept Videos

Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
386
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
165
Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
209
Pneumothorax-II01:27

Pneumothorax-II

Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
720
Pneumothorax-I01:26

Pneumothorax-I

A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
971
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
684